Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR2C2 | P49116 | 7/20 | 0.58 |
| ▸ | HCK | P08631 | 5/20 | 0.58 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | BRAF | P15056 | 3/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | LYN | P07948 | 1/20 | 0.56 |
| ▸ | BCR | P11274 | 1/20 | 0.56 |
| ▸ | BTK | Q06187 | 3/20 | 0.54 |
| ▸ | GCK | P35557 | 2/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | FES | P07332 | 1/20 | 0.54 |
| ▸ | FER | P16591 | 1/20 | 0.54 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3828768 | 0.91 | HCK (0.58) | NR2C2HCKEGFRBRAFABL1 | |
| SCHEMBL13897939 | 0.91 | NR2C2 (0.48) | NR2C2HCKEGFRBRAFABL1 | |
| SCHEMBL3829713 | 0.85 | BRAF (0.54) | HCKBRAFLYN | |
| SCHEMBL1826484 | 0.82 | NR2C2 (0.58) | NR2C2HCKEGFRBRAFGCK | |
| SCHEMBL13897932 | 0.82 | HCK (0.48) | NR2C2HCKEGFRBRAFABL1 | |
| SCHEMBL3823481 | 0.81 | KDR (0.64) | HCKBRAFABL1LYNBTK | |
| SCHEMBL3827617 | 0.80 | HTT (0.59) | NR2C2HCKEGFRBRAFABL1 | |
| SCHEMBL3234828 | 0.80 | NR2C2 (0.59) | NR2C2HCKEGFRBRAFABL1 | |
| SCHEMBL3823342 | 0.79 | LCK (0.65) | HCKBRAFLYNMAPK14 | |
| SCHEMBL3830584 | 0.79 | BRAF (0.55) | HCKBRAFLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | US | claimed |
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069327-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | SRC, BMX, FYN | NR2C2 974/4885HCK 107/4885EGFR 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.